This deal transforms their three-year partnership into full integration, accelerating Illumina's multiomics strategy announced in 2024. The acquisition provides Illumina with SomaLogic's specialized aptamer-based proteomics technology, which has demonstrated strong performance in plexity, scalability, and reproducibility. The SomaScan® Proteomics Assay, already being adapted to Illumina's NGS platforms, allows researchers to analyze thousands of protein markers in a single experiment with high sensitivity. This capability is crucial for complex biomarker discovery and disease profiling. The strategic rationale is compelling: Illumina leverages its dominant NGS infrastructure to enter adjacent markets, creating a more comprehensive multiomics ecosystem while adding a high-margin consumables revenue stream.